The Latest Developments in Alzheimer’s Drugs Disease
New Treatments on the Horizon
Several promising new drugs for Alzheimer's disease are currently in clinical trials. These experimental treatments target various aspects of Alzheimer's pathology and may slow cognitive decline. If successful, they could expand treatment options beyond the existing approved medications.
One class of medications in late-stage trials attempts to reduce amyloid plaques in the brain, a pathological hallmark of Alzheimers Drugs. Amyloid-beta is a protein fragment that aggregates into plaque deposits between neurons. Several antibodies and small molecules aim to clear amyloid or prevent its accumulation.
Aducanumab, an intravenous antibody from Biogen, showed signs of reducing amyloid and slowing cognitive decline in phase 3 trials. However, questions remain about the size and consistency of the treatment effect. Researchers are analyzing additional data to determine if the Alzheimer’s drugs provide a real clinical benefit.
Another anti-amyloid antibody, donanemab from Eli Lilly, also targets a form of amyloid thought to be especially toxic. Early phase 2 data found it significantly reduced amyloid and slowly cognitive decline. A large phase 3 study is ongoing to confirm these initial positive results.
Get More Insights on- Alzheimers Drugs
English
Arabic
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian